Project Grant K08AI180364

Award Date 7/1/24
Completion Date 6/30/28
Dollars Obligated $599K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This $15,981,588 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases aims to develop pan-coronavirus vaccines. Led by Washington University, the collaborative program includes eleven laboratories seeking to design optimized B and T cell antigens conferring broad immunity against sarbecoviruses and merbecoviruses. The three-year award beginning September 2022 supports three integrated research projects and two centralized cores. Project 1...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $899,935 to the Scripps Research Institute to identify novel B cell epitopes on the SARS-CoV-2 spike protein and other human coronaviruses. The goal is to uncover broadly neutralizing antibody epitopes that can inform the design of next-generation COVID-19 vaccines and therapeutics, enhancing pandemic preparedness. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $867,563 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Rockefeller University. The grant supports the development of a pioneering class of nanobodies engineered from llama immune systems to provide comprehensive protection against all betacoronaviruses, including SARS-CoV-1, MERS-CoV, and SARS-CoV-2. Key goals include strategically expanding nanobody repertoires, identifying...
This $2 million cooperative agreement from the National Science Foundation will support Protabit LLC in developing artificial intelligence-enabled antibody engineering approaches to generate neutralizing antibodies against SARS-CoV-2. Funded through Jul 2022 to Jun 2024 under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the project aims to discover a large array of high-affinity neutralizing antibodies targeting multiple regions of the SARS-CoV-2 spike protein. This...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $193,644 to The Trustees of Columbia University in the City of New York to conduct research on the impact of immune imprinting from prior SARS-CoV-2 variant exposure on antibody responses to emerging variants. The key objectives are to: 1) Test the effect of immune imprinting on neutralizing antibody responses in a...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is supporting the development of a unique vaccine to prevent future pandemics caused by emerging coronaviruses. The $755,225 award to Loyola University of Chicago aims to create a T cell-inducing mucosal vaccine targeting conserved coronavirus antigens, which could provide cross-protection against sarbecoviruses and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $464,750 to the Icahn School of Medicine at Mount Sinai to investigate the mechanisms of mucosal immune responses induced by mRNA-based and Newcastle Disease Virus (NDV)-based COVID-19 vaccine platforms. The research aims to understand how these vaccine technologies can prime mucosal B cells and promote their recirculation to induce...
This three-year, $18.13 million project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at the University of Washington and five sub-awardee institutions to develop broadly protective coronavirus vaccines. Under the Allergy and Infectious Diseases Research program, the grantee and sub-awardees will pursue three outputs: tools to study coronaviruses, antibodies for treatment, and vaccine candidates. They will generate reverse...
This $249,999 National Science Foundation project grant supports the development of a bioengineered nanobarrier spray to protect against SARS-CoV-2 and other viral infections of the nasopharynx. Funded under the NSF Engineering program (CFDA 47.041), the two-year award to the University of Southern California will support computational modeling of nanobarrier delivery via nasal applicator as well as efficacy testing in a coronavirus mouse model. Specifically, the university researchers will...
This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...

ENGINEERING IMMUNITY FOR BROAD PROTECTION AGAINST BETACORONAVIRUSES - ABSTRACT IN THE PAST DECADE THREE HIGHLY VIRULENT HUMAN BETACORONAVIRUSES HAVE EMERGED, INCLUDING SARS-COV-2 WHICH HAS CAUSED A DEVASTATING PANDEMIC AND IS RESPONSIBLE FOR THE DEATHS OF OVER 6 MILLION PEOPLE WORLDWIDE. CURRENT VACCINES AND MONOCLONAL ANTIBODY (MAB) TREATMENTS FOR SARS-COV-2 ARE SUSCEPTIBLE TO MUTATIONS IN THE VIRUS WHICH CAN LEAD TO DECREASED EFFICACY OF THESE THERAPIES. TWO OTHER HIGHLY PATHOGENIC HUMAN BETACORONAVIRUSES, SARS-COV AND MERS-COV, HAVE NO APPROVED VACCINES OR THERAPEUTICS. THERE IS AN URGENT NEED FOR BROADLY ACTING ANTIBODIES AND VACCINES WHICH CAN PROTECT AGAINST NEW VARIANTS OF SARS-COV-2 OR FUTURE EMERGING HUMAN BETACORONAVIRUSES. OUR CURRENT VACCINES AND MABS FOR SARS-COV-2 TARGET THE VIRAL SPIKE PROTEIN. THE SPIKE (S) IS NECESSARY AND SUFFICIENT TO MEDIATE ENTRY OF THE VIRUS INTO HOST CELLS. S IS COMPRISED OF TWO SUBUNITS. S1 IS THE RECEPTOR BINDING SUBUNIT AND A MAJOR TARGET OF ANTIBODIES PRODUCED BY CURRENT VACCINES AND MAB THERAPIES. S2 IS THE MEMBRANE FUSION SUBUNIT AND IS HIGHLY CONSERVED AMONG BETACORONAVIRUSES. LITTLE IS KNOWN ABOUT S2 TARGETING ANTIBODIES AND THEIR POTENTIAL USE IN PROTECTING AGAINST BETACORONAVIRUS INFECTIONS. IN THIS PROJECT WE WILL IDENTIFY AND DESIGN BROADLY ACTING S2 ANTIBODIES AS WELL AS INVESTIGATE FC-EFFECTOR FUNCTIONS OF THESE ANTIBODIES. A MULTIPRONGED APPROACH USING NEUTRALIZATION ASSAYS, IN VITRO FC-EFFECTOR FUNCTION ASSAYS AND SYSTEMS SEROLOGY WILL EVALUATE THE FUNCTIONAL PROPERTIES OF S2 ANTIBODIES FROM MICE IMMUNIZED WITH S2 IMMUNOGENS. USING A PANEL OF REPLICATION COMPETENT VESICULAR STOMATITIS VIRUS (RVSV) PSEUDOTYPE VIRUSES EXPRESSING THE SPIKE PROTEIN FROM A WIDE RANGE OF BETACORONAVIRUSES (RVSV-COVS) WE WILL BE ABLE TO IDENTIFY ANTIBODIES THAT ARE BROADLY ACTING. FINALLY, BY USING WHAT WE LEARN IN OUR ANALYSIS OF ENDOGENOUSLY PRODUCED S2 ANTIBODIES WE WILL DESIGN BISPECIFIC S2 TARGETING ANTIBODIES TO DEVELOP NOVEL THERAPEUTICS BROADLY TARGETING BETACORONAVIRUSES. THIS PROJECT WILL SIGNIFICANTLY ADD TO OUR KNOWLEDGE OF THE ROLE S2 ANTIBODIES PLAY IN INFECTION WITH BETACORONAVIRUSES AND HOW THESE ANTIBODIES CAN BE UTILIZED FOR FUTURE PANDEMIC PREPAREDNESS.

Posted 6/18/24